Boomtown

[MyzStreet]

$USRM
Awaiting FDA-RMAT decision.

This year USRM has:

*U.S. Stem Cell, Inc.'s MARVEL Phase II/III Trial Receives Reactivation Status with the FDA
https://www.google.com/amp/s/www.yahoo.com/amphtml/finance/news/u-stem-cell-inc-marvel-130000877.html

*Has received a commitment to invest up to $5,000,000 from private equity firm General American Capital Partners LLC (GACP).
http://www.otcmarkets.com/stock/USRM/news

*US Stem Cell Inc (OTCMKTS:USRM) Stock Has a Powerful New Weapon
According to the latest announcement out of USRM, the company has developed a strategic alliance with Advanced Stem Cell Rx (ASC), a US-based provider of regenerative medicine programs, including the development of autologous stem cell treatment centers throughout the US.
http://oracledispatch.com/2017/04/04/us-stem-cell-inc-otcmktsusrm-stock-powerful-new-weapon/

*Opening 10 stem cell clinics in the U.S. within 3 years. Plus 2.5 million investment.
8-k
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11917807

*William Murphy Jr. reports FORM-4's:
He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame.

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11969212

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11939672

*10-k U.. STEM CELL RELEASES POSITIVE 2016 FINANCIAL RESULTS
https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11933564

*Settled with Northstar, Inc.
http://us-stemcell.com/wp-content/uploads/2017/03/U.S.-Stem-Cell-8-K-03-06-17-Review-v3.pdf

*U.S. Stem Cell, Inc. Reports Continued Positive Results for Q1 2017
Posted by U.S. Stem Cell, Inc
Sunrise, FL – May 3, 2017 – U.S. STEM CELL, Inc., a Florida corporation, a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending March 31, 2017:
* Revenue up by 62% from $710,000 in Q1 2016 to $1.15M in Q1 2017
* Gross profit up by 45.6% from $556,000 in Q1 2016 to $810,000 in Q1 2017
* Cash Flow is positive Q1 2017 at $268,000 compared to Q1 2016 at ($62,000)
* All debt-to-equity convertible notes have been either fully paid or converted as of March 31, 2017.
“We are very pleased with the 2017 improvements in operations and balance sheet performance,” said Mike Tomás, President & CEO of U.S. Stem Cell, Inc. “We are progressing with our principal strategic business initiatives which include growing top line revenues and pursuing new business opportunities for exponential growth.”
U.S. Stem Cell, Inc. continues to make a positive impact on the lives of patients treated using its procedures. This year we hope to continue our accomplishments and value for both patients and shareholders.